Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.27072 http://scihub22266oqcxt.onion/10.1002/jmv.27072 34101851!8242473!34101851     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2021 ; 93 (9): 5277-5284 Nephropedia Template TP {{tp|p=34101851|t=2021. Interferon-alpha position in combating with COVID-19: A systematic review |pdf=|usr=}}{{34101851}} gab.com Text Interferon-alpha position in combating with COVID-19: A systematic review JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=34101851 #FOAvip The newborn coronaivus disease 2019 (COVID-19) pandemic has become the foremost concern of health system worldwide. Interferon typeI (IFN-I) are among the well-known antiviruses. Hence IFN-alpha have gained much attention as a treatment for COVID-19 recently. To sum up the efficiency of IFN-alpha against COVID-19, we searched PubMed, SCOPUS, and EMBASE, from the date of genesis to the 1st of October 2020. Discharge from hospital and virus clearance considered as primary and secondary outcomes, respectively. We compared the aforementioned outcomes of patients treated with standard care protocol and the patients treated with IFN-alpha in addition to standard care protocol. Out of 356 identified records, 14 studies were subjected for full-text screening. Finally, a systematic review was performed with inclusion of five studies. Majority of the participants were males (ranged from 43.50% to 90.0%). We found that time of viral clearance and polymerase chain reaction negative (days) in most studies were decreased in the INF-alpha + standard care group. The mean days of virus's clearance in INF-alpha group and standard group reported 27.3 and 32.43. Likewise, the average days of hospitalization was found also lower in INF-alpha group (18.55 vs. 24.36). This study provides a stand to conclude that early administration of INF-alpha may be accounted as a promising treatment of COVID-19. Twit Text FOAVip Interferon-alpha position in combating with COVID-19: A systematic review ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=34101851 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34101851 #FOAvip English Wikipedia <ref>{{Cite pmid|34101851}}</ref> Interferon-alpha position in combating with COVID-19: A systematic review #MMPMID34101851 Nakhlband A; Fakhari A; Azizi H J Med Virol 2021[Sep]; 93 (9): 5277-5284 PMID34101851show ga The newborn coronaivus disease 2019 (COVID-19) pandemic has become the foremost concern of health system worldwide. Interferon typeI (IFN-I) are among the well-known antiviruses. Hence IFN-alpha have gained much attention as a treatment for COVID-19 recently. To sum up the efficiency of IFN-alpha against COVID-19, we searched PubMed, SCOPUS, and EMBASE, from the date of genesis to the 1st of October 2020. Discharge from hospital and virus clearance considered as primary and secondary outcomes, respectively. We compared the aforementioned outcomes of patients treated with standard care protocol and the patients treated with IFN-alpha in addition to standard care protocol. Out of 356 identified records, 14 studies were subjected for full-text screening. Finally, a systematic review was performed with inclusion of five studies. Majority of the participants were males (ranged from 43.50% to 90.0%). We found that time of viral clearance and polymerase chain reaction negative (days) in most studies were decreased in the INF-alpha + standard care group. The mean days of virus's clearance in INF-alpha group and standard group reported 27.3 and 32.43. Likewise, the average days of hospitalization was found also lower in INF-alpha group (18.55 vs. 24.36). This study provides a stand to conclude that early administration of INF-alpha may be accounted as a promising treatment of COVID-19. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Antiviral Agents/*administration & dosage[MESH] |Clinical Trials as Topic[MESH] |Female[MESH] |Humans[MESH] |Interferon-alpha/*administration & dosage[MESH] |Male[MESH] |Middle Aged[MESH]Interferon-alpha position in combating with COVID-19: A systematic rev(epmc).pdf DeepDyve Pubget Overpricing